Ownership Capital B.V. Has $10.24 Million Stock Position in Veeva Systems Inc. $VEEV

Ownership Capital B.V. lessened its position in Veeva Systems Inc. (NYSE:VEEV) by 89.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,371 shares of the technology company’s stock after selling 286,865 shares during the period. Veeva Systems comprises approximately 5.8% of Ownership Capital B.V.’s holdings, making the stock its 6th biggest holding. Ownership Capital B.V.’s holdings in Veeva Systems were worth $10,239,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Sigma Planning Corp boosted its position in Veeva Systems by 1.2% in the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after buying an additional 39 shares in the last quarter. Private Trust Co. NA raised its stake in shares of Veeva Systems by 17.1% in the third quarter. Private Trust Co. NA now owns 281 shares of the technology company’s stock valued at $84,000 after acquiring an additional 41 shares during the last quarter. Keybank National Association OH boosted its holdings in shares of Veeva Systems by 1.4% in the 2nd quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock worth $889,000 after acquiring an additional 42 shares in the last quarter. Baron Wealth Management LLC grew its position in Veeva Systems by 1.7% during the 3rd quarter. Baron Wealth Management LLC now owns 2,447 shares of the technology company’s stock worth $729,000 after acquiring an additional 42 shares during the last quarter. Finally, Apollon Wealth Management LLC increased its holdings in Veeva Systems by 1.5% during the 3rd quarter. Apollon Wealth Management LLC now owns 2,905 shares of the technology company’s stock valued at $865,000 after purchasing an additional 42 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on VEEV. The Goldman Sachs Group initiated coverage on Veeva Systems in a research note on Tuesday, January 13th. They issued a “sell” rating and a $215.00 price objective on the stock. Wall Street Zen lowered shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. TD Cowen raised shares of Veeva Systems from a “hold” rating to a “buy” rating and boosted their target price for the stock from $297.00 to $380.00 in a research note on Tuesday, October 7th. BTIG Research reissued a “buy” rating and set a $340.00 price target on shares of Veeva Systems in a research note on Friday, November 21st. Finally, Jefferies Financial Group restated a “buy” rating and issued a $330.00 price objective on shares of Veeva Systems in a research report on Monday, November 24th. Eighteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Veeva Systems has an average rating of “Moderate Buy” and an average price target of $308.04.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total transaction of $231,430.00. Following the completion of the transaction, the insider directly owned 23,204 shares in the company, valued at approximately $5,370,101.72. The trade was a 4.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.30% of the company’s stock.

Veeva Systems Price Performance

VEEV opened at $223.72 on Tuesday. The firm has a 50 day simple moving average of $231.51 and a 200 day simple moving average of $266.40. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50. The company has a market cap of $36.78 billion, a price-to-earnings ratio of 43.53, a price-to-earnings-growth ratio of 1.64 and a beta of 1.07.

Veeva Systems (NYSE:VEEV) last released its earnings results on Thursday, November 20th. The technology company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The firm had revenue of $0.81 million during the quarter, compared to analyst estimates of $792.37 million. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.75 EPS. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. As a group, analysts expect that Veeva Systems Inc. will post 4.35 EPS for the current year.

Veeva Systems announced that its board has authorized a stock buyback program on Monday, January 5th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the technology company to repurchase up to 5.5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.